



A monthly report summarizing life science transactions in Washington State.

**BY THE NUMBERS: 112 TRANSACTIONS TOTALING OVER \$5.08B\***  
(YTD)



## DECEMBER TOP TRANSACTIONS

**Tasso** recently raised \$100M led by healthcare investment manager RA Capital to pursue its blood-draw technology. The new funding brings its total equity investment to \$131M. The device collects capillary blood only—equivalent to a finger prick—not venous blood, which can only be collected by a medical professional ([Forbes](#)).

**Tune Therapeutics** has launched with \$40M in new funding and a leadership team peppered with veterans of Seattle cell therapy biotechs. The company has developed a proprietary platform called TEMPO that operates as an epigenomic therapy ([GeekWire](#)).

**CuriBio** has raised \$10M to advance its platforms for drug discovery, based on human stem cells. Curi Bio enables screening of new drugs using cells derived from human tissue, called induced pluripotent stem cells (iPSCs). It specializes in cardiac, musculoskeletal, and neuromuscular models ([GeekWire](#)).

## OTHER TRENDS & HIGHLIGHTS

**Omeros**, a Seattle-based biotech company, has announced it is selling its Omidria franchise to Rayner Surgical Group. Omidria helps to prevent excessive pupil constriction in cataract surgery ([Seattle Inno](#)).

**Life Science Sector** is booming as companies swoop up lab space and raise gobs of cash. Venture capital funding for the life sciences hit record highs nationally, reaching more than \$30B for the 12 months ending this September, according to the report by real estate firm CBRE ([GeekWire](#)).

**University of Washington's** AI protein folding discovery wins 'Breakthrough of the Year' award from Science Magazine. The University of Washington researchers behind this year's award developed a tool called RoseTTAfold that stunned scientists across the physical and life sciences with its speed and accuracy at predicting how proteins form three-dimensional shapes ([GeekWire](#)).

\*Totals have been adjusted from original monthly reports as data has become available.

# TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
01-Dec-2021	Allay Health	Digital Health	Early Stage VC	undisclosed	Seattle
01-Dec-2021	KeyProteo	Biotech	Early Stage VC	undisclosed	Seattle
02-Dec-2021	Tune Therapeutics	Biotech	Early Stage VC	\$40,000,000	Seattle
06-Dec-2021	Lyn Health	Digital Health	Seed Round	\$10,000,000	Seattle
07-Dec-2021	Kitotech Medical	Medtech	Later Stage VC	\$2,600,000	Seattle
10-Dec-2021	Monod Bio	Biotech	Early Stage VC	\$6,000,000	Seattle
16-Dec-2021	Soovu	Medtech	Later Stage VC	\$250,000	Seattle
16-Dec-2021	Tasso	Medtech	Later Stage VC	\$99,470,000	Seattle
21-Dec-2021	Measure Labs	Digital Health	Seed Round	\$4,690,000	Seattle
22-Dec-2021	Bonum Therapeutics	Biotech	Angel (individual)	\$1,190,000	Seattle
22-Dec-2021	Good (Drug Discovery)	Biotech	Later Stage VC	\$8,810,000	Seattle
22-Dec-2021	WEconnect Health Management	Digital Health	Later Stage VC	\$12,020,000	Seattle
29-Dec-2021	Curi Bio	Biotech	Later Stage VC	\$10,000,000	Seattle
<b>December Total (disclosed transactions):</b>				<b>\$195,030,000</b>	
<b>November Total (disclosed transactions):</b>				<b>\$226,890,000</b>	
<b>October Total (disclosed transactions):</b>				<b>\$146,280,000</b>	
<b>September Total (disclosed transactions):</b>				<b>\$84,970,000</b>	
<b>August Total (disclosed transactions):</b>				<b>\$104,260,000 *</b>	
<b>July Total (disclosed transactions):</b>				<b>\$660,550,000</b>	
<b>June Total (disclosed transactions):</b>				<b>\$572,110,000</b>	
<b>May Total (disclosed transactions):</b>				<b>\$14,530,000</b>	
<b>April Total (disclosed transactions):</b>				<b>\$841,190,000</b>	
<b>March Total (disclosed transactions):</b>				<b>\$1,089,960,000</b>	
<b>February Total (disclosed transactions):</b>				<b>\$666,580,000 *</b>	
<b>January Total (disclosed transactions):</b>				<b>\$478,070,000</b>	
<b>2021 Total:</b>				<b>\$5,080,420,000*</b>	

\*Totals have been adjusted from original monthly reports as data has become available.

This report is prepared by Aylin Kim, Manager of Entrepreneurship at LSW Institute. Questions or comments? Contact aylin@lswinstitute.org. \*The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information as of January 23, 2022 at 4:43 PM. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary and post-IPO transactions are not tracked by Life Science Washington Institute.